Long-term results of a RCT | Active maintenance Olaparib vs. Placebo for germline BRCA-mutated metastatic pancreatic cancer.

Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer – Journal of Clinical Oncology (link to abstract – $ for full-text)

Commentary: Maintenance Olaparib vs Placebo in Germline BRCA-Mutated Metastatic Pancreatic Cancer: Overall Survival Analysis of the POLO Trial – The ASCO Post

Commentary on Twitter

OS data from the POLO trial of maintenance olaparib vs placebo for pts with BRCA-mutant PDAC reveal no significant benefit (median 19.0 vs 19.2 months) although the curves separated at 24 months & 3-yr OS was 33.9% vs 17.8%; other outcomes favour olaparib: https://t.co/JZ28MsGV0B

— NatureRevClinOncol (@NatRevClinOncol) July 20, 2022